Pharmaceuticals News

The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025. ...

Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 25 juin 2025 Nantes, le 4 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) annonce...

Documents made available to the shareholders for the combined general meeting of June 25th, 2025 Nantes, June 4th, 2025, 8 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)...

LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the...

OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des programmes clés dans l'inflammation et de l'immuno-oncologie Insuffler un nouvel élan en immunologie et inflammation...

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab...

Saint-Herblain (France), le 4 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA) (la « Société »), société spécialisée dans les vaccins, a annoncé aujourd’hui la mise à disposition des...

Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined...

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety demonstrated in available...

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously...